Literature DB >> 28139862

The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.

Yasunori Sato1, Masahiko Kinoshita2, Shigekazu Takemura2, Shogo Tanaka2, Genya Hamano2, Shoji Nakamori3, Masahiro Fujikawa4, Yasuhiko Sugawara5, Takatsugu Yamamoto6, Akira Arimoto7, Minako Yamamura1, Motoko Sasaki1, Kenichi Harada1, Yasuni Nakanuma8, Shoji Kubo2.   

Abstract

An outbreak of cholangiocarcinoma in a printing company was reported in Japan, and these cases were regarded as an occupational disease (occupational cholangiocarcinoma). This study examined the expression status of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) in occupational cholangiocarcinoma. Immunostaining of PD-1, PD-L1, CD3, CD8, and CD163 was performed using tissue sections of occupational cholangiocarcinoma (n = 10), and the results were compared with those of control cases consisting of intrahepatic (n = 23) and extrahepatic (n = 45) cholangiocarcinoma. Carcinoma cells expressed PD-L1 in all cases of occupational cholangiocarcinoma, whereas the detection of PD-L1 expression in cholangiocarcinoma cells was limited to a low number of cases (less than 10%) in the control subjects. In cases of occupational cholangiocarcinoma, occasional PD-L1 expression was also noted in precancerous/preinvasive lesions such as biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct. Additionally, tumor-associated macrophages and tumor-infiltrating T cells expressed PD-L1 and PD-1, respectively. The number of PD-L1-positive mononuclear cells, PD-1-positive lymphocytes, and CD8-positive lymphocytes infiltrating within the tumor was significantly higher in occupational cholangiocarcinoma compared with that in control cases. These results indicate that immune escape via the PD-1/PD-L1 axis may be occurring in occupational cholangiocarcinoma.
© 2017 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  immune escape; multistep carcinogenesis; occupational cholangiocarcinoma; organic solvent exposure

Mesh:

Substances:

Year:  2017        PMID: 28139862     DOI: 10.1111/pin.12511

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  11 in total

1.  Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.

Authors:  Naoshi Nishida; Kazuko Sakai; Masahiro Morita; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yoriaki Komeda; Mamoru Takenaka; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Kazuto Nishio; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-17       Impact factor: 11.740

Review 2.  Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.

Authors:  Guoying Zhou; Patrick P C Boor; Marco J Bruno; Dave Sprengers; Jaap Kwekkeboom
Journal:  Br J Cancer       Date:  2021-08-16       Impact factor: 9.075

Review 3.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

4.  Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.

Authors:  Richard Kim; Domenico Coppola; Emilie Wang; Young Doo Chang; Yuhree Kim; Daniel Anaya; Dae Won Kim
Journal:  Oncotarget       Date:  2018-05-04

Review 5.  Immune checkpoint therapy in liver cancer.

Authors:  Feng Xu; Tianqiang Jin; Yuwen Zhu; Chaoliu Dai
Journal:  J Exp Clin Cancer Res       Date:  2018-05-29

6.  Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.

Authors:  Jia-Cheng Lu; Hai-Ying Zeng; Qi-Man Sun; Qing-Nan Meng; Xiao-Yong Huang; Peng-Fei Zhang; Xuan Yang; Rui Peng; Chao Gao; Chuan-Yuan Wei; Ying-Hao Shen; Jia-Bing Cai; Rui-Zhao Dong; Ying-Hong Shi; Hui-Chuan Sun; Yujiang G Shi; Jian Zhou; Jia Fan; Ai-Wu Ke; Liu-Xiao Yang; Guo-Ming Shi
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

Review 7.  Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers.

Authors:  Ruyi Zhang; Marco Puzzoni; Stefano Mariani; Yi Zheng; Nicole Liscia; Yixuan Guo; Clelia Donisi; Yu Liu; Valentino Impera; Weijia Fang; Mario Scartozzi
Journal:  Cancer Sci       Date:  2021-10-06       Impact factor: 6.716

8.  Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.

Authors:  Min Deng; Shao-Hua Li; Xu Fu; Xiao-Peng Yan; Jun Chen; Yu-Dong Qiu; Rong-Ping Guo
Journal:  Cancer Cell Int       Date:  2021-07-12       Impact factor: 5.722

Review 9.  Occupational cholangiocarcinoma caused by exposure to 1,2-dichloropropane and/or dichloromethane.

Authors:  Shoji Kubo; Shigekazu Takemura; Shogo Tanaka; Hiroji Shinkawa; Masahiko Kinoshita; Genya Hamano; Tokuji Ito; Masaki Koda; Takanori Aota
Journal:  Ann Gastroenterol Surg       Date:  2017-11-17

Review 10.  Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.

Authors:  Fan-Li Zeng; Jing-Fang Chen
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.